Attached files
| file | filename |
|---|---|
| 10-K - 10-K - ENZON PHARMACEUTICALS, INC. | v461243_10k.htm |
| EX-4.3 - EXHIBIT 4.3 - ENZON PHARMACEUTICALS, INC. | v461243_ex4-3.htm |
| EX-21.1 - EXHIBIT 21.1 - ENZON PHARMACEUTICALS, INC. | v461243_ex21-1.htm |
| EX-31.2 - EXHIBIT 31.2 - ENZON PHARMACEUTICALS, INC. | v461243_ex31-2.htm |
| EX-32.2 - EXHIBIT 32.2 - ENZON PHARMACEUTICALS, INC. | v461243_ex32-2.htm |
| EX-31.1 - EXHIBIT 31.1 - ENZON PHARMACEUTICALS, INC. | v461243_ex31-1.htm |
| EX-32.1 - EXHIBIT 32.1 - ENZON PHARMACEUTICALS, INC. | v461243_ex32-1.htm |
EXHIBIT 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the Registration Statements of Enzon Pharmaceuticals, Inc. and Subsidiaries on Form S-3 (No. 333-137723) and Form S-8 (Nos. 333-174099, 333-140282,333-134453, 333-132467, 333-121468, 333-101898, 333-64110, and 333-18051) of our report dated March 24, 2017, on our audits of the consolidated financial statements as of December 31, 2016 and 2015 and for each of the years then ended, which report is included in this Annual Report on Form 10-K to be filed on or about March 24, 2017.
/s/ EISNERAMPER LLP
Iselin, New Jersey
March 24, 2017